| HOME >> BIOLOGY >> TECHNOLOGY |
SOMERSET, N.J., Aug. 28 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV" or the "Company") (OTC Bulletin Board and Pink Sheets: DOVP) announced today that its common stock is now being quoted on the OTC Bulletin Board. The Company understands that its common stock is also still being quoted on the Pink Sheets.
"We are pleased that shares of our common stock are now being quoted both on the OTC Bulletin Board and the Pink Sheets," said Barbara Duncan, Chief Executive Officer of DOV. "We believe this dual quotation on the OTC Bulletin Board and the Pink Sheets provides the Company with greater visibility in the investment community and offers our shareholders, both current and future, greater liquidity."
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition and development of novel drug candidates for central nervous system disorders. The Company's product candidates address some of the largest pharmaceutical markets in the world including depression, pain and insomnia.
Cautionary Note
Statements in this press release that are not historical facts
constitute forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, each as amended. You can also identify forward-looking statements
by the following words: may, will, should, expect, intend, plan,
anticipate, believe, estimate, predict, potential, continue or the negative
of these terms or other comparable terminology. We caution you that
forward-looking statements are inherently uncertain and are simply
point-in-time estimates based on a combination of facts and factors
currently known by us about which we cannot be certain or even relatively
confident. Actual results or events will surely differ and may differ
materially from our forward-looking statements as a result of many factors,
some of which we may not be able to predict or may not be within our
contro
'/>"/>
| SOURCE DOV Pharmaceutical, Inc. Copyright©2007 PR Newswire. All rights reserved |